#novo-nordisk
Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales
Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies flood the market.
Novo Sees Generic Ozempic Delayed in China Until Next Year
Novo Nordisk A/S expects generic Ozempic to be delayed in China until next year, a positive step for the drugmaker as it battles to keep its share of the global obesity market.